Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fedor, J. M.
Right arrow Articles by Phillips, H. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fedor, J. M.
Right arrow Articles by Phillips, H. R.

Chest, Vol 83, 704-706, Copyright © 1983 by American College of Chest Physicians

ARTICLES

Adverse effects of nifedipine therapy on hypertrophic obstructive cardiomyopathy

JM Fedor, RS Stack, DB Pryor and HR Phillips

A 62-year-old man with obstructive hypertrophic cardiomyopathy was given sublingual nifedipine, 10 mg, during invasive hemodynamic monitoring. After 15 minutes, his left ventricular outflow gradient increased from 22 to 80 mm Hg while arterial pressure fell from 152/70 to 122/64 mm Hg. Left ventricular end-diastolic pressure increased from 15 to 22 mm Hg. These adverse hemodynamic responses may have been a result of vasodilation of the peripheral circulation induced by nifedipine. Thus, some patients with hypertrophic obstructive cardiomyopathy may develop serious hemodynamic compromise when treated with nifedipine.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1983 by the American College of Chest Physicians.